Quisque vel mauris ac
Maecenas eget lacus metus. Pellentesque accumsan faucibus enim
Duis a mauris euismod ex rhoncus tempus. Etiam mi ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Are you ready to better understand and predict drug-induced liver injury before it reaches the clinic? Then join us for an interactive webinar introducing DILIsym® 11, the latest evolution of the industry’s leading quantitative systems toxicology (QST) platform. Designed to predict clinical liver safety outcomes, DILIsym integrates in vitro mechanistic data with physiologically based pharmacokinetic (PBPK) predictions of liver drug concentrations. In this webinar, you’ll learn about: • New Predictive Mechanisms: Explore how the addition of T cell–mediated adaptive immune responses advances immune-related DILI simulation. • Expanded SimPops: Model pediatric populations and diverse patient profiles to support safer, more inclusive drug development. • Enhanced Sub-Models: Discover refinements in the simulation of cholestatic injury and other liver injury types, enabling more accurate scenario testing. The webinar will also feature a live software demonstration and an interactive Q&A. Don’t miss this opportunity to see the latest advances in liver safety science and software. Register now.
Thursday, October 2, 2025
8:00 am - 9:00 am PDT
Senior Principal Scientist and Associate Director, QSP Dr. Yang’s has largely focused on the computational modeling of drug-induced liver injury (DILI) regarding interference of bile acid transport by hepatotoxic drugs. Dr. Yang has also led efforts to predict the impact to biomarkers of liver health and function due to disruptions of hepatocyte biochemistry (e.g., transporter function). Dr. Yang also utilizes DILIsym in proprietary projects to help evaluate DILI risk for sponsor compounds in clinical development. Dr. Yang received her B.S. in pharmacy and M.S. in pharmacokinetics from Seoul National University, South Korea, and Ph.D. in Pharmaceutical Sciences from University of North Carolina at Chapel Hill. Her graduate research focused on defining the mechanisms of DILI involving the interactions in efflux of bile acids and drugs. As a result of her research, she earned numerous fellowship awards. Dr. Yang has published scientific papers in the areas of drug metabolism and transport, regulation of drug metabolizing enzymes during pregnancy, and systems pharmacology modeling of DILI. She has been invited to speak at multiple scientific meetings including the FDA DILI Conference and ASCPT Annual Meeting.
Simulations Plus
Senior Director, Business Development (Moderator) Since joining Simulations Plus in 2017, Dan is dedicated to representing the needs of our clients to our team of scientists so that we may provide expert modeling and simulation software, solutions, and services… on time, on spec, and on budget. Dan is a business development expert with 30 years of experience in alliance management and business development for the pharma/biotech industry. Skilled in B2B sales, networking, and growing relationships with customers and prospects. Strong international relations with North America, LATAM, EU, APAC and MEA markets.
Simulations Plus
Speaker Title 3
Speaker Company 3Enter Text Here
Speaker Title 4
Speaker Company 4Enter Text Here
Speaker Title 5
Speaker Company 5Enter Text Here
Speaker Title 6
Speaker Company 6Enter Text Here
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!